Phase II clinical trial of 4′-O-Tetrahydropyranyl-Adriamycin (THP-Adriamycin) in recurrent squamous cell carcinoma of the head and neck
- 19 Downloads
Summary
Fourteen patients previously treated with surgery, radiotherapy, and/or chemotherapy for primary squamous cell carcinoma of the head and neck were treated with 4′-O-tetrahydropyranyl-Adriamycin (THP-adriamycin) for locally or distantly recurrent disease. The starting dose was 60 mg/m2 by i.v. infusion, with courses repeated every 3 to 4 weeks. A total of 34 courses of treatment were delivered (median, 2; range, 1–6). All patients were evaluable for response and toxicity. There were no responses. Severe (grade 3 or 4) neutropenia occurred in 11 patients. Thrombocytopenia, anemia, and gastrointestinal toxicity were modest, and no hepatic, renal, or cardiac toxicity was observed. The lack of response in association with severe neutropenia and moderate other toxicities using this dose and schedule of THP-Adriamycin should be taken into consideration prior to the pursuit of further study of this compound in a similar patient population.
Key words
phase II THP-Adriamycin squamous cell carcinoma of head and neckPreview
Unable to display preview. Download preview PDF.
References
- 1.Umezawa H: Tetrahydropyranyl derivatives of daunomycin and Adriamycin. J Antibiot (Tokyo) 32: 1028–1084, 1979Google Scholar
- 2.Umezawa H, Yamada K, Oki T: Comparative experimental studies on 4′-O-tetrahydropyranyl-Adriamycin and Adriamycin. In: Mathe G, Maral R, De Jager R (eds) Anthracyclines. Masson Publishing, New York, 1983, pp 183–188Google Scholar
- 3.Dantchev D, Paintrand M, Hayat M, Bourut C, Mathe G: Low heart and skin toxicity of a tetrahydropyranyl derivative of Adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo) 32: 1085–1086, 1979Google Scholar
- 4.Sridhar KS, Samy TS, Koch G, Agarwal P, Duncan RC, Ganz W, Benedetto P, Feun L, Savaraj N, Gross J, Krishan A, Zubrod CG: Phase I study of 4′-O-tetrahydropyranyladriamycin. In: Advances in Experimental and Clinical Chemotherapy. Fifteenth International Congress of Chemotherapy, Workshop Pirarubicin, July 19–24, 1987, Istanbul, Turkey. ECOMED, West Germany, 1987, pp 11–26Google Scholar
- 5.Raber MN, Newman RA, Lu K, Legha S, Gorski C, Benjamin RS, Krakoff IH: Phase I clinical trial and pharmacokinetic evaluation of 4′-O-tetrahydropyranyl-Adriamycin (THP-Adriamycin). Cancer Chemother Pharmacol 23: 311–315, 1989Google Scholar
- 6.Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 204–214, 1981Google Scholar